人无娇妻中日久久持久久_灌牛奶cao哭男男腐纯肉_AV无码A片高潮AV_秋霞网在线伦理影片_欧美性爱第1页_墨武新书_国产精口品美女乱子伦高潮_国产精品人妻系列21P_色婷婷狠狠18禁久久YYY_金龙神枪_老师带我去没人的地方做

AACR 2024 Poster Resources

April 10, 2024
Preclinical PD-1 Resistance Models: Crucial Tools for Unveiling PD-1 Resistance Mechanisms and Advancing Novel Treatment Strategies

Preclinical PD-1 Resistance Models: Crucial Tools for Unveiling PD-1 Resistance Mechanisms and Advancing Novel Treatment Strategies

The interaction between PD-1 and PD-L1 promotes tumor immune evasion, but immune checkpoint inhibitors can reinvigorate the immune system. However, most patients don't respond well to anti-PD-1/PD-L1 therapy, leading to acquired resistance. Establishing reliable preclinical resistance models is vital for understanding resistance mechanisms and developing new treatments.
Download
NeoMab?: A Novel Platform for Fully Human Therapeutic Antibody Development

NeoMab?: A Novel Platform for Fully Human Therapeutic Antibody Development

Antibodies and related therapies have shown promise in treating human diseases, but challenges like immunogenicity and limited preclinical models hinder drug development. GemPharmatech's NeoMab? mouse model addresses these issues by producing fully human antibodies, offering robust immune responses and high-affinity antibodies against various antigens. Utilizing human genes, NeoMab? accelerates the discovery of human antibody drugs, potentially surpassing FDA-approved treatments.
Download
Patient-derived xenograft (PDX) models with differential HER2 expression for preclinical evaluation of HER2-targeted therapies

Patient-derived xenograft (PDX) models with differential HER2 expression for preclinical evaluation of HER2-targeted therapies

HER2 overexpression is common in gastric and gastroesophageal cancer, emphasizing the need to target HER2 in treatment. Gempharmatech offers PDX gastric cancer models with varying HER2 levels, identified through immunohistochemistry. These models, exemplified by one with heterogeneous HER2 expression, provide detailed insights into drug responses, particularly highlighting the efficacy of Trastuzumab deruxtecan, contributing to precision medicine in HER2-targeted therapy development.
Download
Development of a Novel Murine Model, NCG-M/hIL15, for Enhanced Post-HSC Transplantation Immunoreconstruction

Development of a Novel Murine Model, NCG-M/hIL15, for Enhanced Post-HSC Transplantation Immunoreconstruction

The NCG-M/hIL15 model represents a significant advancement in preclinical research by addressing limitations in existing murine models related to human immune responses, particularly in natural killer (NK) cell and myeloid lineage cell reconstitution post-HSC transplantation. This model demonstrates improved reconstitution of NK cells, T cells, and myeloid lineage cells compared to conventional models, enhancing the simulation of human immune responses and offering potential benefits for studying immunology and developing novel therapies.
Download
Development and Application of the NCG-hIL2 Mouse Model: A Humanized Platform for Enhanced NK Cell Evaluation in ADCC Efficacy Testing

Development and Application of the NCG-hIL2 Mouse Model: A Humanized Platform for Enhanced NK Cell Evaluation in ADCC Efficacy Testing

The NCG-hIL2 mouse model, engineered to express human Interleukin-2 (IL2), facilitates the reconstitution of human NK cells, aiding in the assessment of therapeutic antibodies' efficacy, notably in ADCC. This model enhances our understanding of NK cell development and serves as a valuable tool for studying immunotherapies, particularly in cancer treatment.
Download
BALB/c-hIL12RB1/hIL12RB2: A Robust Model for Preclinical Research in Human IL-12 Therapy

BALB/c-hIL12RB1/hIL12RB2: A Robust Model for Preclinical Research in Human IL-12 Therapy

Recent interest in Interleukin-12 (IL-12) as a therapeutic target led to the development of the BALB/c-hIL12RB1/hIL12RB2 humanized mouse model, preserving intracellular signaling and effectively expressing human IL12RB1 and IL12RB2. This model demonstrates enhanced activation of cytotoxic lymphocytes, natural killer cells, and interferon production, validating IL-12 as a potential anti-tumor drug target. Successful validation of the model suggests its utility in understanding IL-12's therapeutic mechanisms and developing novel anti-tumor treatments.
Download
Breaking Through ADCs Resistance: Constructing Preclinical Enhertu-induced Resistant Model

Breaking Through ADCs Resistance: Constructing Preclinical Enhertu-induced Resistant Model

Antibody-drug conjugates (ADCs) have shown significant efficacy in HER2-positive breast cancer, but the emergence of resistance underscores the need to understand resistance mechanisms. Preclinical models, like the Enhertu-resistant tumor model developed from continuous Enhertu treatment in JIMT-1 tumor tissues in mice, offer insights into resistance mechanisms involving various cellular components within the tumor microenvironment. These models serve as valuable tools for predicting and understanding ADC resistance, aiding in the development of strategies to overcome resistance in clinical settings.
Download

人无娇妻中日久久持久久_灌牛奶cao哭男男腐纯肉_AV无码A片高潮AV_秋霞网在线伦理影片_欧美性爱第1页_墨武新书_国产精口品美女乱子伦高潮_国产精品人妻系列21P_色婷婷狠狠18禁久久YYY_金龙神枪_老师带我去没人的地方做